OmniAb, Inc.
Annah Lee, Ph.D., MPH has a diverse work experience in various research and clinical settings. Annah is currently working as a Research Scientist at OmniAb, Inc. since February 2023. Prior to this, they worked as a Scientist - Cell Line Development and Tissue Engineering at Orbillion Bio (YC W21) from November 2021 to January 2023.
In 2020, Annah served as a Postdoctoral Researcher at City of Hope from December 2020 to November 2021. Before that, they were a Graduate Assistant Researcher at Texas A&M University from August 2016 to December 2020. At Texas A&M, they conducted research on avian immunology, focusing on Salmonella Enteritidis functional pathway during the host-pathogen interaction. Annah also worked as a Graduate Teaching Assistant for Microbiology during August 2017 to December 2017.
Prior to their time at Texas A&M, Annah gained research experience as a Senior Research Technician at Genentech from February 2016 to August 2016, where they dosed murine models with therapeutic drug compounds and performed blood collection techniques. Annah also worked as a Pathology Tech Assistant at Kaiser Permanente from May 2013 to August 2016, where they grossed and dictated small biopsies and assisted pathologists during autopsies.
Annah's earlier roles include being a Graduate Research Intern at Colorado State University from August 2015 to December 2015, where they prepared a gap-analysis manuscript for publication, and an Intern - Practicum at USDA-APHIS from March 2015 to July 2015, where they worked on data analysis and drafting publications. Annah also worked as a Research Technician at Colorado State University from October 2014 to May 2015, where they conducted qRT-PCR experiments for stem cell therapy research.
During their early career, Annah worked as a Research Assistant at Lawrence Berkeley National Laboratory from July 2011 to May 2013. Overall, Annah Lee, Ph.D., MPH has accumulated significant experience in research, laboratory techniques, and academic teaching throughout their career.
Annah Lee, Ph.D., MPH has a strong educational background in the field of animal sciences and public health. Annah completed their Bachelor of Science (BS) degree in Animal Sciences from the University of California, Davis, spanning from 2007 to 2011. Following that, they pursued a Master of Public Health (M.P.H.) degree in Public Health at Colorado State University, completing it between 2014 and 2015. Annah continued to expand their knowledge and expertise by obtaining a Doctor of Philosophy (PhD) degree with a focus on Poultry Science at Texas A&M University from 2016 to 2020.
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.